Cargando…
Corrigendum to: Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010280/ https://www.ncbi.nlm.nih.gov/pubmed/35001534 http://dx.doi.org/10.1111/cts.13223 |
Ejemplares similares
-
Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
por: Eudy‐Byrne, Rena, et al.
Publicado: (2021) -
481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome
por: Tobacyk, Julia, et al.
Publicado: (2023) -
Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021) -
Single high-dose buprenorphine for opioid craving during withdrawal
por: Ahmadi, Jamshid, et al.
Publicado: (2018) -
Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
por: Chavan, Niraj R., et al.
Publicado: (2017)